Editorial: Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?

Expert Review of Clinical Immunology

Volumn 6, Issue 3, 2010, Pages 319-321

  Brannagan III, Thomas H ^a   Patterson, Shanna K ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; EDITORIAL; HEALTH CARE COST; HUMAN; LYMPH NODE IRRADIATION; PLASMAPHERESIS; REMISSION; UNSPECIFIED SIDE EFFECT; ADULT; AUTOIMMUNE THYROIDITIS; FEMALE; HEMATOLOGIC DISEASE; POLYRADICULONEUROPATHY; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; PLASMA EXCHANGE; PLASMAPHERESIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROIDITIS, AUTOIMMUNE; YOUNG ADULT;

EID: 77952014915     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.23     Document Type: Editorial

References (28)

1. Brannagan TH 3rd. Immune-mediated chronic demyelinating polyneuropathies. In: Neuroimmunology in Clinical Practice. Kalman B, Brannagan TH III (Eds). Blackwell, Oxford, UK, 123-138 (2008).
2. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassifed neuropathies yields improved diagnosis. Ann. Neurol. 10 (3), 222-226 (1981).
3. Barohn RJ. Approach to peripheral neuropathy and neuronopathy. Semin. Neurol. 18 (1), 7-18 (1998).
4. Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry 66 (5), 677-680 (1999).
5. Brannagan TH. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve 39 (5), 563-578 (2009).
6. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48 (2), 321-328 (1997).
7. McCrone P, Chisholm D, Knapp M et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 10 (6), 687-694 (2003).
8. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 43 (8), 1801-1808 (2000).
9. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am. J. Kidney Dis. 33 (5), 829-839 (1999).
10. Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J. Neurol. Neurosurg. Psychiatry 77 (6), 800-802 (2006).
11. Oyama Y, Sufit R, Loh Y et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 69 (18), 1802-1803 (2007).
12. Mahdi-Rogers M, Kazmi M, Ferner R et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J. Peripher. Nerv. Syst. 14 (2), 118-124 (2009).
13. Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J. Neurol. Neurosurg. Psychiatry 79 (5), 612-614 (2008).
14. Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 72 (1), 127-128 (2002).
15. Vermeulen M, Van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J. Neurol. Neurosurg. Psychiatry 78 (10), 1154 (2007).
16. Remenyi P, Masszi T, Borbenyi Z, Soos J, Siklos L, Engelhardt JI. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur. J. Neurol. 14 (8), E1-E2 (2007).
17. Brannagan TH, Pradhan A, Heiman-Patterson T et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58 (12), 1856-1858 (2002).
18. Gladstone DE, Golightly MG, Brannagan TH III. High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. J. Neuroimmunol. 190 (1-2), 121-126 (2007).
19. Hu Y P, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128 (2), 260-270 (2009).
20. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119 (7), 2052-2061 (2009).
21. Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253 (1), 98-108 (2006).
22. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 11 (1), 30-46 (2006).
23. Marsh EA, Hirst CL, Llewelyn JG et al. Alemtuzumab in the treatment of IVIG-dependent chronic inammatory demyelinating polyneuropatfhy. J. Neurol. (2010) (Epub ahead of print).
24. Walsh M, Chaudhry A, Jayne D. Longterm follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67 (9), 1322-1327 (2008).
25. Coles AJ, Compston DAS, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359 (17), 1786-1801 (2008).
26. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis. 43 (1), 16-24 (2006).
27. Nath DS, Kandaswamy R, Gruessner R, Sutherland DER, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc. 37 (2), 934-936 (2005).
28. Hattori N, Misu K, Koike H et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 184 (1), 57-63 (2001).